» Articles » PMID: 23649826

Risk Factors for False Positive and for False Negative Test Results in Screening with Fecal Occult Blood Testing

Overview
Journal Int J Cancer
Specialty Oncology
Date 2013 May 8
PMID 23649826
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Differences in the risk of a false negative or a false positive fecal immunochemical test (FIT) across subgroups may affect optimal screening strategies. We evaluate whether subgroups are at increased risk of a false positive or a false negative FIT result, whether such variability in risk is related to differences in FIT sensitivity and specificity or to differences in prior CRC risk. Randomly selected, asymptomatic individuals were invited to undergo colonoscopy. Participants were asked to undergo one sample FIT and to complete a risk questionnaire. We identified patient characteristics associated with a false negative and false positive FIT results using logistic regression. We focused on statistically significant differences as well as on variables influencing the false positive or negative risk for which the odds ratio exceeded 1.25. Of the 1,426 screening participants, 1,112 (78%) completed FIT and the questionnaire; 101 (9.1%) had advanced neoplasia. 102 Individuals were FIT positive, 65 (64%) had a false negative FIT result and 66 (65%) a false positive FIT result. Participants at higher age and smokers had a significantly higher risk of a false negative FIT result. Males were at increased risk of a false positive result, so were smokers and regular NSAID users. FIT sensitivity was lower in females. Specificity was lower for males, smokers and regular NSAID users. FIT sensitivity was lower in women. FIT specificity was lower in males, smokers and regular NSAID users. Our results can be used for further evidence based individualization of screening strategies.

Citing Articles

Stool-Based Colorectal Cancer Screening Test Performance Characteristics in Those With and Without Hemorrhoids.

Ebner D, Rushlow D, Mou J, Porter K, Finney Rutten L, Limburg P Mayo Clin Proc Innov Qual Outcomes. 2023; 7(4):320-326.

PMID: 37502338 PMC: 10371761. DOI: 10.1016/j.mayocpiqo.2023.06.003.


Faecal haemoglobin concentrations are associated with all-cause mortality and cause of death in colorectal cancer screening.

Kaalby L, Deding U, Al-Najami I, Berg-Beckhoff G, Bjorsum-Meyer T, Laurberg T BMC Med. 2023; 21(1):29.

PMID: 36691009 PMC: 9872406. DOI: 10.1186/s12916-022-02724-3.


Comparison of Findings From Fecal Occult Blood Test and Esophagogastroduodenoscopy With Histopathology Among Symptomatic Saudi Adults: A Retrospective Study.

Alhuzaim W, AlNojaidi J, AlKhalaf S, Almalki S, AlDosari Y, Abualnaja A Cureus. 2023; 14(12):e33119.

PMID: 36601186 PMC: 9803864. DOI: 10.7759/cureus.33119.


Using fecal immunochemical tubes for the analysis of the gut microbiome has the potential to improve colorectal cancer screening.

Krigul K, Aasmets O, Lull K, Org T, Org E Sci Rep. 2021; 11(1):19603.

PMID: 34599256 PMC: 8486803. DOI: 10.1038/s41598-021-99046-w.


Predictive Modeling of Colonoscopic Findings in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program.

Law J, Rajan A, Trieu H, Azizian J, Berry R, Beaven S Dig Dis Sci. 2021; 67(7):2842-2848.

PMID: 34350518 PMC: 9237000. DOI: 10.1007/s10620-021-07160-6.